Relmada Therapeutics (RLMD)
(Delayed Data from NSDQ)
$3.83 USD
+0.13 (3.51%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $3.83 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth B Momentum D VGM
Cash flow Statements
Fiscal Year End for Relmada Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -98.79 | -157.04 | -125.75 | -59.46 | 0.00 |
Depreciation/Amortization & Depletion | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change from Assets/Liabilities | 3.08 | 10.59 | -7.86 | 10.85 | 0.00 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 44.05 | 42.65 | 41.74 | 20.79 | 0.00 |
Net Cash From Operating Activities | -51.66 | -103.80 | -91.87 | -27.81 | 0.00 |
Property & Equipment | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 50.45 | 19.73 | -54.12 | -34.45 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 50.45 | 19.73 | -54.12 | -34.45 | 0.00 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 0.00 | 44.70 | 187.94 | 28.58 | 0.00 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | -0.11 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -0.10 | 0.32 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | -0.10 | 45.02 | 187.94 | 28.47 | 0.00 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -1.30 | -39.05 | 41.95 | -33.78 | 0.00 |
Cash at Beginning of Period | 5.40 | 44.44 | 2.50 | 36.28 | 0.00 |
Cash at End of Period | 4.09 | 5.40 | 44.44 | 2.50 | 0.00 |
Diluted Net EPS | -3.28 | -5.30 | -7.16 | -3.81 | -2.76 |
Fiscal Year End for Relmada Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -98.79 | -73.63 | -51.62 | -26.32 |
Depreciation/Amortization & Depletion | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change from Assets/Liabilities | NA | 3.08 | -2.35 | -0.69 | -0.91 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 44.05 | 34.56 | 22.54 | 10.73 |
Net Cash From Operating Activities | NA | -51.66 | -41.41 | -29.78 | -16.51 |
Property & Equipment | NA | 0.00 | 0.00 | 0.00 | -34.77 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | 50.45 | 42.71 | 38.85 | 74.77 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | 50.45 | 42.71 | 38.85 | 40.00 |
Uses of Funds
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Issuance (Repayment) of Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | -0.10 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | NA | -0.10 | 0.00 | 0.00 | 0.00 |
Effect of Exchange Rate Changes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | NA | -1.30 | 1.30 | 9.07 | 23.50 |
Cash at Beginning of Period | NA | 5.40 | 5.40 | 5.40 | 5.40 |
Cash at End of Period | NA | 4.09 | 6.70 | 14.47 | 28.89 |
Diluted Net EPS | NA | -0.84 | -0.73 | -0.84 | -0.87 |